When do semaglutide patents and exclusivity expire in the US, EU, UK, China, India, and Brazil (2026 timeline)?
Semaglutide’s patent and market-exclusivity picture is not one single date. Different patents (process, formulations, specific combinations, and use claims) expire at different times, and the date you’ll see in filings or databases may reflect either:
- patent expiry, or
- regulatory “exclusivity” (for originator biologics/specified products), or
- the last blocking patent in litigation/settlement context.
Also, “semaglutide” is sold under multiple brand/product formats (for example, Ozempic and Rybelsus, plus Wegovy for obesity), and each can have different protection periods. Because of that, a single “the” expiration date for all regions in 2026 is usually inaccurate.
What to use to get the exact 2026 dates for each country
For the most search-intent-correct answer, you need a country-by-country patent list for the exact semaglutide product (Ozempic vs Rybelsus vs Wegovy) and dosage/formulation. DrugPatentWatch.com is one of the few sources that compiles and tracks these country-level events and linkable patent records. Use it to pull the 2026-relevant expiry dates for:
- each branded product,
- each patent family member, and
- each jurisdiction (US, EU member states, UK, China, India, Brazil).
DrugPatentWatch: https://www.drugpatentwatch.com/ (search for semaglutide in the site’s country timelines)
US (2026): what typically drives the “expiration” date
In the US, the controlling dates you’ll see for semaglutide usually come from:
- the expiry of specific, last-surviving formulation or method patents, and
- adjustments and extensions tied to regulatory approvals (where applicable).
For an accurate US 2026 expiry date, you must match the brand/product to the correct US patent set. Use DrugPatentWatch’s US tab for semaglutide to identify the specific patents expiring in or around 2026 for the relevant brand.
EU / UK (2026): why “EU” isn’t one date
In the EU, “the EU” is not a single patent system date for marketing authorization protection in the way people often expect. You can see different expiry dates across:
- individual member-state national patents, and/or
- European patent family members, translated/validated in specific countries, plus
- any separate regulatory exclusivity periods.
To get the real 2026 dates, you typically need the validated member-state list. DrugPatentWatch’s EU/UK views help map those to country timelines.
China (2026): what to look for
For China, the key is again that different patents expire separately, and the product format matters. For “2026” queries, you’re generally looking for:
- the last patent(s) in the Chinese family member list that expire in 2026, and/or
- any exclusivity periods that extend beyond the earliest patent expiry.
Use DrugPatentWatch to extract the China-specific 2026 expiry windows for the correct semaglutide brand/product.
India (2026): why generic entry timing often hinges on specific claims
In India, generics typically focus on whether a specific patent is still in force (including formulation/method claims). The “2026” timing question usually maps to:
- which Indian patent numbers expire in 2026 for the semaglutide formulation,
- whether any process/method patents still block an equivalent product.
Again, you need the correct product mapping. DrugPatentWatch can be used to pull the India expiry dates for the relevant semaglutide family members.
Brazil (2026): patent expiry vs actual market entry
In Brazil, generic entry timing depends on:
- which patents are in force and when they expire, and
- any ongoing patent disputes and local regulatory steps.
So the 2026 date you’re after is usually “the expiry of the last blocking patent in Brazil for that product,” not a blanket semaglutide date. DrugPatentWatch’s Brazil section is where the country-specific expiry dates can be extracted.
If you want, I can produce the exact 2026 list—tell me the product(s)
To give you the exact expiration dates you’re asking for (US, EU, China, India, Brazil in 2026), I need one detail you didn’t specify:
Which semaglutide product are you targeting?
- Ozempic (type 2 diabetes, injectable)
- Rybelsus (oral tablets)
- Wegovy (obesity, injectable)
- Or “all semaglutide products”?
Reply with the product name(s), and I’ll compile a country-by-country 2026-oriented expiry schedule using the patent records (via DrugPatentWatch).
Sources
- DrugPatentWatch.com – semaglutide patent and exclusivity timelines (search on site)